PRINCETON, N.J.– Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today announced the hiring of George Landau as Executive Vice President (EVP) of Business Development and Commercialization. As EVP, Landau will oversee strategic partnerships and commercialization for Orthobond and its proprietary antibacterial, non-eluting surface solution, OSTAGUARD.
“We are pleased to welcome George to our executive leadership team during this transformative time for Orthobond,” said David Nichols, CEO of Orthobond. “With George’s indispensable expertise and proven track record of success within the medical device industry, we are poised to tackle the next stage of our company’s growth. This strategic appointment furthers our unwavering commitment to bringing breakthrough solutions to the fight against bacterial contamination of medical device implants.”
Mr. Landau brings over three decades of strategic initiative experience in the life-science industry to the Orthobond team. With a proven track record in business and corporate development across medical device, pharmaceutical, and digital health sectors, he has successfully led numerous high-profile mergers, acquisitions, and partnerships. His expertise spans market planning, competitive analysis, commercial operations, deal development and transaction execution, with a particular focus on driving growth, innovation and value. Prior to joining Orthobond, Mr. Landau was President of Alpha MedTech Advisors, a consulting firm providing advisory and transaction focused services for strategic development and business growth. Before AlphaMedTech Advisors, he held several executive roles at ConvaTec Group, PLC., CR Bard, Inc., TYRX, Inc., Tengion, Inc., and Johnson & Johnson’s Cordis Corporation, where he oversaw identification and implementation of strategic merger and acquisition opportunities and new business development.
“I am thrilled to be joining Orthobond during this exciting moment in its growth trajectory and to help expand and accelerate its commercialization efforts,” said Mr. Landau. “The company’s achievements to date and its commitment to reducing bacterial contamination on medical device implants is inspiring, and I look forward to contributing my experience in strategic partnerships and commercial development to further strengthen our impact in the orthopedic space and other clinical areas where value can be provided.”
